INTRODUCTION
Docking is a successful method in computer-aided drug design. 1-5 However, there is a large and increasing discrepancy between the number of small molecules available in computer-readable format (on the order of 10 7 -10 8 compounds, 6 not counting those generated by de novo design programs) and the amount of molecules that can be efficiently processed by high-throughput approaches in silico or in vitro (on the order of 10 5 -10 6 ). Moreover, it is highly inefficient to use computational resources or robotic systems and chemical reagents for compounds that have a low chance of binding to the target protein. The essential question is how to utilize (structural) information of the target to preselect the molecules that are most likely to show binding and inhibitory activity. One efficient approach exploits the available experimental knowledge of known inhibitors by using pharmacophore constraints to preselect compounds for docking, thereby reducing computation times. In this way, inhibitors of aldose reductase 7 and the MDM2 oncoprotein 8 were identified.
Here, we introduce an efficient computational method to focus a library (termed ALTA for anchor-based library tailoring) and present an application which has resulted in the discovery of inhibitors of the erythropoietin producing human hepatocellular carcinoma receptor tyrosine kinase B4 (EphB4). The basic strategy of the ALTA approach ( Fig. 1) has been inspired by in silico fragment-based approaches 10,13 and in vitro ''needle screening'' procedures. 14 Needle-or anchor-based in vitro screening has been applied to a wide range of enzymes including thrombin, 14 DNA gyrase, 15 and protein tyrosine kinases. 16,17 Therefore, although only one kinase is used in this study to validate the approach, the applicability of ALTA extends to any target enzyme for which the three-dimensional structure and substrate binding site are known.
The receptor tyrosine kinase EphB4 is a highly attractive angiogenic target involved in many types of cancer. 18 It seems to be rather recalcitrant to inhibition because, despite its potential therapeutic importance, only two ABSTRACT High-throughput docking is a computational tool frequently used to discover small-molecule inhibitors of enzymes or receptors of known three-dimensional structure. Because of the large number of molecules in chemical libraries, automatic procedures to prune multimillion compound collections are useful for highthroughput docking and necessary for in vitro screening. Here, we propose an anchor-based library tailoring approach (termed ALTA) to focus a chemical library by docking and prioritizing molecular fragments according to their binding energy which includes continuum electrostatics solvation. In principle, ALTA does not require prior knowledge of known inhibitors, but receptor-based pharmacophore information (hydrogen bonds with the hinge region) is additionally used here to identify molecules with optimal anchor fragments for the ATP-binding site of the EphB4 receptor tyrosine kinase. The 21,418 molecules of the focused library (from an initial collection of about 730,000) are docked into EphB4 and ranked by force-field-based energy including electrostatic solvation. Among the 43 compounds tested in vitro, eight molecules originating from two different anchors show low-micromolar activity in a fluorescence-based enzymatic assay. Four of them are active in a cell-based assay and are potential anti-angiogenic compounds.
series of nonpeptidic small molecule inhibitors have been reported in the literature up to date. 19 This work reports on the efficient docking of a focused compound library, tailored by ALTA to the ATP-binding site of EphB4. The docking of the focused library results in the identification of several small molecules that are promising anti-angiogenic lead compounds against EphB4.
METHODS

Computational methods
The procedure for ALTA starts from a large pool of compounds and consists of six steps, which are illustrated in Figure 1 together with the statistics of the application to EphB4. It is important to underline that although a suite of in-house developed softwares was used in this study, the basic workflow can be reproduced with any combination of softwares that is capable of carrying out all the steps. Three libraries were combined for a total of 728,202 compounds: the NCI database, 20 the ChemDiv library (Moscow, Russia), and the synthetic and natural compound library of InterBioScreen (Moscow, Russia). In
Step 1 of ALTA, the compounds were decomposed into predominantly rigid fragments by automatic identification and cutting of rotatable bonds. 9 The three fragments with the highest chemical richness (sum over the entries in the molecular fingerprint; cf. Fig. 2 in Ref. 9) were selected for every compound. From the resulting set of 35,513 unique fragments, candidate anchors were chosen which fulfil the constraints imposed by the binding site (Step 2 in Fig. 1 ). Although it is not a requirement of ALTA to take pharmacophore constraints into account, doing so will help to discard at an early stage fragments which are unlikely to bind. In this study, the ability of a fragment to form the characteristic bidentate hydrogen bonds of ATP with the hinge region of a kinase 21 was used. Fragments that contained at least one ring, one hydrogen bond donor (nitrogen, oxygen, or sulfur connected to a hydrogen), and one acceptor (nitrogen with a lone pair or oxygen) were docked with a rigid-fragment docking program 10,11 ( Step 3 in Fig. 1 ). The presence of a ring was required to select only fragments with a certain rigidity and thus fixed relative orientation of the donor and acceptor group(s). Docked fragments were considered to form the bidentate hydrogen bonds if a matching donor and acceptor were found within a radius of 3 Å around the carbonyl oxygen of Glu694 and the amide nitrogen of Met696, respectively. Glu694 and Met696 are the first and last residue in the hinge region of EphB4. These fragments were ranked according to their binding energy (Step 4 in Fig. 1) , which is the sum of van der Waals interaction, electrostatic desolvation of both the receptor and the fragment, and the screened electrostatic interaction. 10 There are no terms reflecting the internal energy, since fragments are treated as rigid. Using the 1205 top-ranking fragments as queries, 21,418 compounds were retrieved from the composite library of 728,202 molecules (Step 5 in Fig. 1 ). This search used an algorithm for the identification of a graph-subgraph isomorphism 22 which was implemented in DAIM, 9 adapting the VFLib Graph Matching Library, version 2.0 in Ref. 23 . Finally, in Step 6, a suite of programs was used for fragment-based 9,10 flexible-ligand docking by genetic algorithm optimization. 12 The protein was kept rigid during docking, but two structures with different orientations of the hydroxyl group of Thr693 were used for both fragment and compound docking in order to allow for a greater variety of eventual hydrogen bond interactions with potential ligands. The third column in the table of Figure 1 lists the numbers of unique fragments (or compounds), whereas the fourth Figure 1 Graphical representation of the workflow of the ALTA procedure (top) and its application to EphB4 (bottom). The first step is the automatic decomposition 9 of a library of compounds (orange rectangle) to obtain the pool of fragments. Afterward, fragments selected based on the binding site features are docked 10 and ranked according to their binding energy. 11 Poses for molecules that contain at least one of the top-ranking fragments are then generated by flexible-ligand docking. 12 a Number of fragments/compounds processed in the individual steps. Docking (Steps 3 and 6) was carried out in parallel on two structures of EphB4 differing only in the orientation of the hydroxyl group of Thr693 in the ATPbinding site. The value of N mol is the number of unique fragments (in Steps 3-5) or unique molecules (in Step 6) originating from the docking into the two structures. In contrast, N common is the number of fragments or molecules that were docked to both structures. As an example, there are 1205 unique anchor fragments, 795 of which have favorable binding energy in both EphB4 structures, upon merging the two sets of 1000 fragments (one set for each Thr693 orientation) with most favorable binding energy calculated by SEED. Maximum diversity set (mds): flexibleligand docking using the three fragments which are most dissimilar to each other as anchors. The compounds docked using the mds are a subset of the compounds docked using the mis.
column lists the fragments selected for (or compounds docked into) both structures.
EphB4 model
Since the crystal structure of the kinase domain of EphB4 is not known, a homology model was built using the structure of EphB2 (mouse, PDB entry 1JPA 24 ) as template. The overall amino acid sequence identity between the human EphB4 sequence obtained from SWISS-PROT (accession code P54760) and the sequence derived from the mouse EphB2 structure is 88.4% and there are no gaps or insertions in the aligned region. An additionally generated binary sequence alignment with the sequence derived from the human Eph kinase structure EphA2 (PDB entry 1MQB) revealed a lower sequence identity of 63.1% and also three short regions containing gaps or insertions. Therefore, only the sequence alignment between EphB4 (human) and EphB2 (mouse) was used in the initial phase of the homology modeling procedure. All sequence alignments were performed using the program ClustalW. 25 The 1JPA crystal structure comprises two chemically identical subunits in the crystallographic asymmetric unit. A structural superposition of the two subunits results in an average rootmean square deviation of 0.32 Å for 269 C a atoms. Since subunit A of the 1JPA crystal structure has better mainchain dihedral angles (/ and w) and lower B factors, this subunit was initially chosen as the template structure. However, the two subunits of the 1JPA structure show some clear structural differences around the active site region. The differing amino acid residues were analyzed with respect to B factors, possible contacts, and stereochemical criteria. Subsequently, the side-chain rotamer conformations of the initial template structure (subunit A) were replaced by the corresponding side-chain conformations of subunit B of the 1JPA crystal structure, if the latter were better defined according to the aforementioned criteria. The resulting modified structure was then used as template for homology modeling and a total of 100 different models were generated using the program Modeller. 26, 27 The obtained initial models were ranked and analyzed based on internal energy and stereochemical quality. The best model was manually modified by comparison with the active sites of the two known Eph kinase structures (PDB entry codes 1JPA and 1MQB) and other related kinase structures (PDB entry codes 1BYG, 1FMK, 1FPU, 1IEP, 1M14, 1M17, 1M52, 1MP8, 1OPK, 1OPL, and 2SRC) found by PSI-BLAST 28 and DALI 29 searches of protein structure databases. The conformational information contained in these homologous structures was used for manually adjusting side-chain conformations of conserved or similar amino acid residues. If feasible on the basis of energetic and packing criteria, side-chain vangles of the respective amino acid residues were completely or partially conserved. Or else, statistically preferred v-angles were chosen and favorable hydrophobic or polar contacts were taken into consideration. After each manual change, the side-chain in question was minimized with CHARMM 30 and the CHARMm22 31 force field. Moreover, an ATP molecule was modeled into the active site to avoid structural changes during minimization. Hydrogen atoms (considering appropriate ionization states for acidic and basic amino acid residues), CHARMm22 31 atom types, and partial charges were assigned to the protein and ATP using the program WITNOTP and the MPEOE method. 32, 33 This rebuilding and refinement with CHARMM 30 using the CHARMm22 31 force field led to a model exhibiting excellent stereochemical quality, with 92.9% of the //w values in the most favored regions and 6.3% in additionally allowed regions of the Ramachandran plot as evaluated with the program PROCHECK. 34 Finally, the ATP molecule was removed.
Minimization and ranking
After docking, multiple poses of each compound were minimized with CHARMM 30 and the CHARMm22 31 force field. Minimized poses were filtered according to thresholds in van der Waals energy and van der Waals efficiency (the ratio of the van der Waals energy and the molecular weight) (Supplementary Materials). A general linear interaction energy with continuum electrostatics (LIECE 35 ) model 36 was used for the final ranking (see the next paragraph).
LIECE model for kinases
The two-parameter LIECE model DG 5 aDE vdW 1 bDG elec was developed using a composite set of 165 known inhibitors, that is, 73, 51, and 41 inhibitors of cyclin-dependent kinase 2 (CDK2), lymphocyte-specific kinase (Lck), and p38 mitogen-activated protein kinase (p38), respectively. It showed a very low root-meansquare of the error (rmse) of only 1.03 kcal/mol for the 165 inhibitors used as training set in the fitting and a leave-one-out cross-validated q 2 of 0.74. 36 The values of a and b for this kinase LIECE model are 0.2898 AE 0.0075 (model with all 165 inhibitors AE standard deviation over 165 LIECE models obtained by leave-one-out) and 0.0442 AE 0.0074, respectively. The values of these parameters are similar to those obtained for the three models derived by fitting to each of the three kinases individually. The two-parameter three-protein LIECE model was also cross validated on a set of compounds not used for fitting, namely 128 known inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase. 37 On this set, the model yielded an rmse of 1.46 kcal/mol. This transferability of parameters is in contrast to our previous study, 35 where parameters were not transferable between HIV-1 protease (a 5 0.1690 and b 5 0.0168 using 24 peptidic inhibitors) and b-secretase (a 5 0.2737 and b 5 0.1795 using 13 peptidic inhibitors). The nontransferability between retroviral and mammalian aspartic proteases is due to the fact that they differ not only in overall shape (HIV-1 protease is a homodimer of 99 3 2 residues while human b-secretase is a monomer of 501 residues) but also, and more importantly for LIECE, in the substrate-binding site. This difference stems from the different polypeptide sequences of their substrates. In contrast, the ATP-binding site of kinases, which was targeted in this study, is highly conserved in structure. 21
Kinetic assay
Compound 2 was tested in the Omnia Tyr Recombinant Kit KNZ4051 (Biosource, USA) at different concentrations between 50 nM and 100 lM in a Corning 96-well microtiter plate. Fluorescence progress curves were measured upon excitation at 360 nm and emission at 485 nm. The assay contained a final concentration of EphB4 and ATP of 25 ng/lL and 125 lM (which is near its K m ), respectively, and was run at 308C for 1 h. To provide evidence for specific binding, a second assay was performed in which 0.01% of Triton X-100 was added to the reaction mixture (Fig. 2) . Moreover, to show the competitive behaviour of compound 2 toward ATP, different ATP concentrations (ranging from 31.25 to 500 lM) were used (Fig. 3) . IC 50 values (inhibitor concentration at which enzyme activity is reduced by 50%) and fitted curves were determined with GraphPad Prism 5.0 (GraphPad Software).
Phospho-EphB4 ELISA of CHO cells
The ELISA assay was performed essentially as described in Ref. 39 . Briefly, Chinese hamster ovary (CHO)-FRT cells were stably transfected with myc-tagged full-length human EphB4 according to the Flip-In System protocol (Invitrogen, USA). A clone that expressed myc-tagged human EphB4 and showed inducible autophosphorylation of EphB4 upon stimulation with mouse ephrinB2-Fc (mouse ephrinB2 fused to the Fc region of human IgG) was selected. Cells of this clone were preincubated with Figure 3 Specific velocity plot 38 for compound 2. v 0 /v i is the ratio of the initial velocities for the noninhibited and inhibited reactions at a given ATP concentration. All values were measured in duplicates, but some of the pairs of data points (especially the blue ones) almost completely overlap on the plot. r is the ratio of the ATP concentration and its K m , which was 158 mM in this experiment. ATP concentrations ranged from 31.25 to 500 mM. Intersecting of all curves close to (1, 1) indicates that compound 2 is ATP-competitive. Measurements were carried out by the Omnia kinetic assay as described.
EphB4 inhibitors for 15 min and then stimulated with preclustered ephrinB2-Fc for 45 min at 378C. Cells were lysed, transferred to a 96-well plate coated with anti-myc antibody and incubated overnight at 48C. After incubation with antiphosphotyrosine antibody, reactions were developed with BM Blue peroxidase substrate, and autophosphorylation of EphB4 was quantified by measuring absorption at 450 nm.
RESULTS AND DISCUSSION
Library tailoring by ALTA using the EphB4 structure
Only fragments involved in two or more hydrogen bonds with the EphB4 hinge region were considered in ALTA. Fragments were ranked according to binding energy calculated by SEED (which includes continuum electrostatics solvation). The union of the two sets of 1000 fragments (one set for each protein structure differing in the orientation of the hydroxyl group of Thr693, see Methods section) with the most favorable calculated binding energy consists of 1205 unique fragments. A subset of 21,418 compounds was retrieved from the composite library of 728,202 molecules (Step 5 in Fig. 1 ) using these 1205 fragments.
In vitro validation
Forty compounds from the high-throughput docking of the focused library of 21,418 molecules were selected upon ranking (Step 6 in Fig. 1 ) and tested first in a fluorescence-resonance energy transfer (FRET)-based enzymatic assay (see Supplementary Materials). Ten of these could not be measured, because they interfered with the fluorescence read-out. A compound with a phenylurea anchor (1 in Table I ) showed an IC 50 of 76 lM in the FRET-based enzymatic assay. In the same assay, another compound with a three-ring system as anchor (2 in Table  I ) showed an IC 50 of about 1.6 lM, with a molecular weight of only 353 Da. Five more compounds with different anchors inhibited the activity of EphB4 by 15-40% at a concentration of 125 lM (data not shown).
The ligand efficiency (LE 5 2DG binding exp /HAC, where HAC is the number of heavy atoms) is a useful measure for lead selection. 40 Notably, inhibitor 2 has an LE value of 0.3 kcal/mol per heavy atom suggesting that it is an interesting compound for further development. To evaluate its cell permeability and cellular activity, compound 2 was tested in CHO cells for inhibition of EphB4 autophosphorylation in a mammalian cell-based environment. It showed only mild inhibitory effects in CHO cells at a concentration of 20 lM. To further investigate cellular activity and determine whether lack thereof is a general problem of this class of molecules, 13 molecules containing the scaffold of compound 2 were purchased (of these, only compound 3 was present in the original library. It had been ranked among the first 300 molecules but was not purchased in the first round because it was considered too similar to compound 2). Two of the 13 compounds (3 and 4) showed low-micromolar inhibitory activity in the enzymatic assay. Four more compounds displayed activity in the mid-micromolar range, with similar activities when tested in CHO cells (5) (6) (7) (8) . The similar potency of inhibitors 2-8 is consistent with the binding mode obtained by docking (Fig. 4) , in which the flexible tail is not involved in direct interactions with atoms in the ATP-binding site.
The compounds showing the strongest inhibition effects in the enzymatic assay (2 and 3 in Table I ) were verified in a FRET-based enzymatic assay 41 offered by Cerep (France; see Supplementary Materials). Similar values of IC 50 as compared with the original FRET-based enzymatic assay were obtained (Table I) .
As a representative of the entire series, inhibitor 2 was investigated further to provide evidence against unspecific binding due to compound aggregation. The Omnia kinetic assay (see Methods section) was performed under two conditions, with and without the addition of detergent (0.01% of Triton X-100). The IC 50 values of inhibitor 2 in the two experiments are 5.6 and 7.9 lM, which corresponds to a K i of 2.7 and 2.9 lM, respectively (Fig. 2) . Such detergent-insensitive inhibition is indicative of specific binding. 42 To further analyze the competitive behaviour of inhibitor 2, different ATP concentrations were used in the Omnia kinetic assay (ranging from 31.25 to 500 lM). The data obtained in these experiments is shown in a specific velocity plot 38 (Fig. 3) , where the ratio of the initial velocities for the noninhibited and inhibited reactions at a given ATP concentration (v 0 /v i in Fig. 3 ) is plotted versus r/(11r), with r 5 [ATP]/K m . For an ATP-competitive inhibitor, all curves should intersect close to the point (1,1) , which is the case for inhibitor 2. This result provides strong evidence that inhibitor 2 does indeed bind to the ATP binding site, as predicted by the docking calculations (Fig. 4) .
Interestingly, for both compounds 1 and 2, most of the predicted poses of the anchor fragment and the whole molecule showed significant overlap. In general, small fragments docked in multiple orientations. These docking results are consistent with a recent X-ray study of the binding modes of a 1-lM inhibitor of b-lactamase and its constitutive fragments. 43
Computational requirements
It is interesting to compare the CPU time required for the preparation and docking of the focused library with docking of all compounds in the three libraries. The ALTA approach required about 6500 h (on a Linux cluster with CPUs with clock speeds of 1.7 GHz): 2 h for decomposition into fragments, 2200 h for fragment docking, 1000 h for substructure search, and 3300 h for flexible-ligand docking and CHARMM minimization. 30 The focused library contains 1/34th of the initial collection of compounds and only about 1/3rd of the fragments, which yields a net speedup by a factor of about 20, a number that would be even larger in the case of flexible-protein docking. Although the actual computation times per compound will naturally vary for other docking programs, the speedup achieved by library preprocessing with the ALTA procedure will remain significant.
CONCLUSIONS
The number of available small molecules is growing steadily and is already too large for docking with accurate binding energy evaluation and prohibitive for in vitro screening. In this article, an automatic fragmentbased procedure for focusing libraries of compounds (termed ALTA) was presented and validated. First, molecular fragments are docked and prioritized (i.e., anchors are selected based on a ranking) according to force field energy which includes continuum electrostatics solvation. Large collections of molecules can then be effectively reduced in size by selecting only the compounds for which one of the constitutive fragments is similar to one of the top ranking anchors.
In principle, ALTA does not require any information about known ligands but in the application presented here pharmacophore knowledge (hydrogen bonds to the hinge region of the receptor tyrosine kinase EphB4) was additionally used to efficiently reduce the size of the original library from about 730,000 to 21,418 molecules. Two series of novel EphB4 inhibitors have been identified in this study. The overall hit rate is very high because only 43 compounds were tested in vitro: first 30 molecules suggested by the ALTA approach, and in a second phase 13 compounds with the same anchor (a three-ring system) as the most potent of the seven micromolar inhibitors among the 30 molecules. Compound 2 is a potential candidate for further development for three reasons. First, its low-micromolar affinity and molecular weight of only 353 Da result in a favorable ligand efficiency (binding free energy per heavy atom). Second, the kinetic characterization of compound 2 indicates that it binds to the ATP-binding site, as predicted by the docking calculations. This finding is useful for structure-based lead improvement, for example, by chemical synthesis of derivatives. Finally, derivatives 5-8 have shown inhibitory activity in cell-based assays.
The successful application of the ALTA approach suggests that the identification, based on the structure of the active site, of anchor fragments and their use for library filtering is an efficient strategy for inhibitor discovery by screening in silico. Besides its usefulness for highthroughput docking, other possible applications of ALTA include the design of combinatorial libraries and the focusing of large collections of molecules for high-throughput or NMR-based screening in vitro.
